Bluebird bio Company Overview

Bluebird bio logo
Bluebird bio
Bluebird bio primary media

About Bluebird bio

Bluebird bio (NASDAQ:BLUE) is a biotechnology company focused on developing gene therapies for severe genetic diseases and cancer. The company is known for its pioneering work in gene editing and cell therapy, aiming to create treatments that can offer profound and durable benefits to patients. Its pipeline includes projects targeting conditions like sickle cell disease, beta-thalassemia, and multiple myeloma. With a commitment to addressing some of the most challenging medical conditions, Bluebird bio seeks to transform the landscape of genetic medicine through its innovative approaches and dedication to patients' well-being.

What is Bluebird bio known for?

Snapshot

1992
Year founded
323
Employees
Somerville, United States
Head office
Loading Map...

Operations

All Locations
Somerville, US

Products and/or services of Bluebird bio

  • Zynteglo, a gene therapy for beta-thalassemia, a blood disorder that reduces the production of hemoglobin.
  • LentiGlobin, a gene therapy under development for sickle cell disease, aiming to reduce or eliminate episodes of pain.
  • skysona, a gene therapy for cerebral adrenoleukodystrophy, a rare genetic disorder affecting the brain and adrenal glands.
  • BB305 Lentiviral Vector, a gene therapy product targeting various hematologic and genetic disorders by inserting functional genes into patients' cells.
  • Lenti-D, an experimental gene therapy for treating adrenoleukodystrophy, specifically focusing on stopping the progression of cerebral adrenoleukodystrophy.
  • Gene therapy platform, utilizing lentiviral vectors for the development of treatments for genetic diseases, including cancer.

Bluebird bio executive team

  • Mr. Andrew ObenshainPresident, CEO & Director
  • Mr. Thomas J. KlimaChief Commercial & Operating Officer
  • Mr. Joseph D. Vittiglio Esq., J.D.Chief Legal & Business Officer and Secretary
  • Mr. Oliver James Sterling IIICFO & Principal Accounting Officer
  • Ms. Andrea WaltonChief People Officer
  • Dr. Richard A. Colvin M.D., Ph.D.Chief Medical Officer
  • Mr. Scott ShoemakerSenior Vice President of Technical Operations

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.